Navigate Up

Transplant Immunology Lab

Research Project Description

Composite tissue transplantation

Major soft-tissue and skeletal defects, including limb amputation, represent a deficit of form and function, as well as diminution of life quality for the affected individuals. However, any reconstructive measures to improve these non–life-threatening conditions must address a delicate balance of risks and benefits. As composite tissue transplant experiments are being conducted, a number of human hand transplants have been performed worldwide. These allografts have required an intense maintenance regimen of medications, subjecting the recipients to the significant morbidities of chronic, systemic immunosuppression. To address the risk/benefit ratio, our laboratory investigates novel techniques aiming for the induction of donor-specific tolerance to composite tissue allografts and for minimization of long-term immunosuppression. Specifically, rejection of the skin as the most immunogeneic component or a composite tissue allograft is addressed and targeted with cellular as well as pharmacological treatment.

Preliminary results of pre-clinical testing indicate that tolerance to the musculoskeletal portions of grafts as well as prolongation of skin graft survival can be achieved.

More specifically, cell-based strategies to induce tolerance include the utilization of regulatory cells such as dendritic cells. In collaboration with Dr. Angus Thomson, the tolerogenic properties of dendritic cells in composite tissue allotransplantation are investigated. Especially when kept immature, these unique antigen-presenting cells show distinct abilities for promoting graft acceptance. Our laboratory is focusing on the use of host dendritic cells as carriers of foreign peptide and inducers of donor-specific tolerance. We propose to utilize donor antigen-pulsed host dendritic cells, in conjunction with antilymphocyte serum and rapamycine, to induce tolerance to composite tissues allografts in an orthotopic hind-limb transplant model.

For the induction of tolerance to any composite tissue allograft bearing a skin component, mechanisms involved in skin allograft rejection are of exceptional importance. Hence, current and future research focuses on the induction of tolerance to the epidermal elements. For this purpose, we investigate the effect of a variety of compounds for immunosuppression of the skin component while avoiding or minimizing systemic immunosuppression.

The second major pace-limiting factor in composite tissue allotransplantation is the often unsatisfactory quality and velocity of nerve regeneration. Acceptable functional outcomes have been achieved in some patients after hand and face transplantation; in other cases, however, motor and even more sensory function has remained unsatisfactory. With this regard, strategies for monitoring nerve regeneration after face and hind limb transplantation have been developed and now serve as the basis to test components that may positively influence nerve regeneration.

Our research is considered translational research and particular attention is paid to the clinical situation when designing experiments. All compounds and methods applied are in clinical use or tested in clinical studies for different inflammatory diseases and considered promising for future use in clinical composite tissue allotransplantation.

Key investigators: W.P. Andrew Lee, MD, Stefan Schneeberger, MD

Personnel

Current members of the transplant lab:

Vijay Gorantla, MD, PhD
Postdoctoral Scholar
Project: Harnessing the Immune Privilege of Skin Adnexae for Tolerance Induction to Composite Tissue Limb Allografts
9/06–present

Kia McLean, MD
Resident, Plastic Surgery
Project: A Funtional Hemifacial Allograft Model in the Rat
7/06-present

Mario Solari, MD
Resident, Plastic Surgery
Project: The Immunogenicity of Skin in Transplantation Tolerance
7/06–present

Jignesh Unadkat, MD
Research Fellow
Project: Prevention of chronic rejection in composite tissue
9/05–present

Paul Afrooz, MD
Research Fellow
Project: Harnessing the Immune Privilege of Skin Adnexae for Tolerance Induction to Composite Tissue Limb Allografts
07/07-present

Benson Pulikkottil, MD
Research Fellow
Project: Local Administration of Migratory Inhibitors for Topical Immunosuppression in Composite Tissue Allotransplantation
07/07-present

Douglas Marsteller, BS
Research Associate II
Project: Composite Tissue Allotransplantation
4/06–present

Rami Zanoun, BS
Medical Student
Project: Composite Tissue Allotransplantation
6/07–present

Facilities

In-vitro experiments are conducted in the Thomas E. Starzl Transplantation Institute. The laboratory is fully equipped with sterile hoods, centrifuges, incubators, two microscopes, and safety devices like eyewash and shower. The Starzl Transplantation Institute has many shared core facilities such as flow cytometry analyzer, flow sorter, ELISA plate reader, MLR cell harvester and scintillation counter, and equipment for histopathological tissue processing (microtome), immunohistochemical staining, and confocal microscopy. 

Contact Us

SaraBeth Probst
3550 Terrace Street
690 Scaife Hall
Pittsburgh, PA 15261
O: 412-648-9207
F: 412-383-8986
E-mail: probstsb@upmc.edu

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com